Strategy for enhancing the therapeutic efficacy of histone deacetylase inhibitor dacinostat: the novel paradigm to tackle monotonous cancer chemoresistance (Q41203569)

From Wikidata

Jump to navigation Jump to search

scientific article published on 19 October 2015

Language	Label	Description	Also known as
English	Strategy for enhancing the therapeutic efficacy of histone deacetylase inhibitor dacinostat: the novel paradigm to tackle monotonous cancer chemoresistance	scientific article published on 19 October 2015

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 September 2017

Strategy for enhancing the therapeutic efficacy of histone deacetylase inhibitor dacinostat: the novel paradigm to tackle monotonous cancer chemoresistance (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 September 2017

author name string

Shabir Ahmad Ganai

1

1 reference

Europe PubMed Central

PubMed publication ID

28 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

19 October 2015

1 reference

Europe PubMed Central

PubMed publication ID

28 September 2017

Archives of Pharmacal Research

1 reference

Europe PubMed Central

PubMed publication ID

28 September 2017

Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3.

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0673-9

21 January 2018

Effect of Arsenic Trioxide on QT Interval in Patients With Advanced Malignancies

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0673-9

21 January 2018

Chlamydocin analogs bearing carbonyl group as possible ligand toward zinc atom in histone deacetylases.

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0673-9

21 January 2018

Isoform-selective histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0673-9

21 January 2018

Inhibition of histone deacetylase for the treatment of biliary tract cancer: a new effective pharmacological approach

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0673-9

21 January 2018

Histone deacetylase (HDAC) inhibitors attenuate cardiac hypertrophy by suppressing autophagy

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0673-9

21 January 2018

NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0673-9

21 January 2018

RAFTK/PYK2-dependent and -independent apoptosis in multiple myeloma cells.

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0673-9

21 January 2018

The bone marrow stromal microenvironment influences myeloma therapeutic response in vitro

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0673-9

21 January 2018

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0673-9

21 January 2018

Histone deacetylase inhibitors in hematological malignancies and solid tumors

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0673-9

21 January 2018

HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0673-9

21 January 2018

Organising evidence on QT prolongation and occurrence of Torsades de Pointes with non-antiarrhythmic drugs: a call for consensus

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0673-9

21 January 2018

Histone deacetylases (HDACs): characterization of the classical HDAC family

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0673-9

21 January 2018

QT interval prolongation among patients treated with angiogenesis inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0673-9

21 January 2018

Inhibition of class I histone deacetylases unveils a mitochondrial signature and enhances oxidative metabolism in skeletal muscle and adipose tissue

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0673-9

21 January 2018

Panobinostat: The Small Molecule Metalloenzyme Inhibitor with Marvelous Anticancer Activity

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0673-9

21 January 2018

Energy-optimised pharmacophore approach to identify potential hotspots during inhibition of Class II HDAC isoforms

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0673-9

21 January 2018

HDAC inhibition through valproic acid modulates the methylation profiles in human embryonic kidney cells

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0673-9

21 January 2018

Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating histone deacetylase 6

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0673-9

21 January 2018

The roles of FLT3 in hematopoiesis and leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0673-9

21 January 2018

Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0673-9

21 January 2018

Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0673-9

21 January 2018

Acute myeloid leukemia: advances in diagnosis and classification

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0673-9

21 January 2018

Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0673-9

21 January 2018

Carfilzomib and pomalidomide: recent advances in the treatment of multiple myeloma

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0673-9

21 January 2018

A histone deacetylase inhibitor enhances killing of undifferentiated thyroid carcinoma cells by p53 gene therapy

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0673-9

21 January 2018

Heat shock protein 90 as a molecular target for cancer therapeutics

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0673-9

21 January 2018

The histone deacetylase inhibitor valproic acid alters growth properties of renal cell carcinoma in vitro and in vivo.

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0673-9

21 January 2018

Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0673-9

21 January 2018

Therapeutic application of histone deacetylase inhibitors for central nervous system disorders

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0673-9

21 January 2018

Clinical and therapeutic aspects of congenital and acquired long QT syndrome

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0673-9

21 January 2018

Histone acetylation and deacetylation in yeast

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0673-9

21 January 2018

Panobinostat: a review of trial results and future prospects in multiple myeloma

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0673-9

21 January 2018

Crystal structure of the nucleosome core particle at 2.8 A resolution

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0673-9

21 January 2018

Novel generation of agents with proven clinical activity in multiple myeloma.

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0673-9

21 January 2018

Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0673-9

21 January 2018

Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0673-9

21 January 2018

A single supratherapeutic dose of vorinostat does not prolong the QTc interval in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0673-9

21 January 2018

Phosphorylation of histone H3: a balancing act between chromosome condensation and transcriptional activation

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0673-9

21 January 2018

Human ether-a-go-go related gene (hERG) K+ channels: function and dysfunction

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0673-9

21 January 2018

Mechanisms of drug induced QT interval prolongation.

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0673-9

21 January 2018

The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0673-9

21 January 2018

Deacetylase activity is required for recruitment of the basal transcription machinery and transactivation by STAT5.

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0673-9

21 January 2018

Histone deacetylase inhibitors in lymphoma and solid malignancies

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0673-9

21 January 2018

N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824).

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0673-9

21 January 2018

HDAC6 is a target for protection and regeneration following injury in the nervous system

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0673-9

21 January 2018

Drug-induced prolongation of the QT interval

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0673-9

21 January 2018

The role of histone deacetylases (HDACs) in human cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0673-9

21 January 2018

Apoptotic and autophagic cell death induced by histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0673-9

21 January 2018

The role of FLT3 in haematopoietic malignancies

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0673-9

21 January 2018

Molecularly targeted oncology therapeutics and prolongation of the QT interval

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0673-9

21 January 2018

Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0673-9

21 January 2018

Histone deacetylase inhibitor NVP-LAQ824 has significant activity against myeloid leukemia cells in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0673-9

21 January 2018

Pleiotropic antitumor effects of the pan-HDAC inhibitor ITF2357 against c-Myc-overexpressing human B-cell non-Hodgkin lymphomas.

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0673-9

21 January 2018

Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0673-9

21 January 2018

Trichostatin A sensitizes HBx-expressing liver cancer cells to etoposide treatment

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0673-9

21 January 2018

The emerging role of class II histone deacetylases

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0673-9

21 January 2018

Identifiers

10.1007/S12272-015-0673-9

0 references

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41203569&oldid=2204385910"